Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. Xu M, Zhao J, Zhu L, Ge C, et al. J Hepatol 2025;82:277-300.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xu M, Zhao J, Zhu L, Ge C, et al. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. J Hepatol 2025;82:277-300.
PMID: 39260704